How India Exports Alprazolam to the World

In the United States, alprazolam is approved for the treatment of anxiety and panic disorders. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for alprazolam, indicating a competitive generic market. Notably, the reference listed drug, Niravam (alprazolam orally disintegrating tablets), was subject to patents that expired on April 9, 2018, facilitating the entry of generic versions. The substantial export volume from India to the U.S. underscores the country's role in supplying generic alprazolam to meet American demand.

In the European Union, alprazolam is authorized for the treatment of anxiety disorders. The European Medicines Agency (EMA) oversees the approval and monitoring of medicinal products, ensuring compliance with Good Manufacturing Practice (GMP) standards. Similarly, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) regulates alprazolam, aligning with EMA guidelines. Manufacturers exporting to these regions must adhere to stringent quality and safety standards to obtain and maintain marketing authorizations.

Alprazolam is included in the World Health Organization's (WHO) Model List of Essential Medicines, highlighting its importance in healthcare systems worldwide. The drug is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality specifications across different regions.

In India, alprazolam is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for dispensation. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, alprazolam is not listed under price control. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of psychotropic substances, ensuring compliance with international conventions.

The primary patents for alprazolam have expired, leading to a robust generic market. This patent expiration has enabled multiple manufacturers, including Indian pharmaceutical companies, to produce and export generic versions, contributing to the competitive pricing and widespread availability of the drug globally.

In November 2025, the EMA conducted a periodic safety update report single assessment (PSUSA) for alprazolam, resulting in the maintenance of its current regulatory status, affirming its established safety profile. (ema.europa.eu)

In February 2026, the UK's Advisory Council on the Misuse of Drugs (ACMD) recommended the classification of zuranolone, a drug with a similar mechanism to alprazolam, as a Class C substance under the Misuse of Drugs Act 1971, reflecting ongoing regulatory attention to substances affecting the central nervous system. (gov.uk)

These developments underscore the dynamic regulatory environment surrounding psychotropic medications, emphasizing the need for exporters to stay informed about international regulatory changes to ensure compliance and market access.

Alprazolam, a widely used anxiolytic, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency exposes the supply chain to risks associated with geopolitical tensions, trade restrictions, and production disruptions in China. For instance, in 2020, environmental regulations in China led to the shutdown of several chemical plants, causing significant delays in the supply of KSMs to Indian manufacturers.

To mitigate such vulnerabilities, the Indian government introduced the Production Linked Incentive (PLI) scheme in 2020, aiming to boost domestic production of APIs and KSMs. Despite these efforts, as of 2026, the pharmaceutical industry continues to face challenges in reducing its reliance on Chinese imports due to factors like high production costs and stringent environmental regulations in India.

Our proprietary trade data from 2022 to 2026 indicates a high concentration in Alprazolam exports from India. The top five exporters account for 82.2% of the total export value, with WATSON PHARMA PRIVATE LIMITED alone contributing 46.5%. Such concentration poses significant risks; any operational or regulatory issues faced by these key suppliers could disrupt the entire supply chain.

The PLI scheme, initiated in 2020, was designed to encourage diversification and bolster domestic API production. While it has led to increased investments in the sector, the impact on reducing supplier concentration has been limited. As of 2026, the market remains dominated by a few major players, indicating that further measures are necessary to promote a more balanced supplier landscape.

Recent geopolitical events have further strained the Alprazolam supply chain. The ongoing conflict in the Middle East, particularly the Iran war, has severely disrupted global shipping routes. The Strait of Hormuz, a critical passage for global commerce, has seen halted oil tanker movements, affecting not only oil supply but also the distribution of pharmaceuticals from India. Approximately 3,200 ships are stalled within the Persian Gulf, causing worldwide logistical shortages and rising prices.

Additionally, the Red Sea and Suez Canal have experienced increased instability due to regional conflicts, leading companies like Maersk to reroute ships around Africa’s Cape of Good Hope. This detour adds significant delays and fuel surcharges, further complicating the timely delivery of pharmaceuticals. Air cargo options are also under pressure due to closed airspace in several Middle Eastern countries, stranding high-value goods such as pharmaceuticals.

• Diversify API and KSM Sources: Encourage the development of alternative suppliers in different geographic regions to reduce dependency on a single country.

• Enhance Domestic Production: Strengthen initiatives like the PLI scheme to promote local manufacturing of APIs and KSMs, thereby reducing reliance on imports.

• Develop Strategic Reserves: Establish buffer stocks of critical raw materials and finished products to cushion against supply chain disruptions.

• Invest in Supply Chain Visibility: Implement advanced tracking and monitoring systems to identify potential disruptions early and respond proactively.

• Foster Supplier Relationships: Build strong partnerships with multiple suppliers to ensure flexibility and resilience in the supply chain.

RISK_LEVEL: HIGH